Association Between Diabetes Mellitus and In-Stent Restenosis at a Military Hospital in Jakarta

Alrio Fransisco Hamonangan Hutapea; Taureni Hayati; Ardhestiro Harnindyo Putro

doi:10.30701/ijc.1939

Alrio Fransisco Hamonangan Hutapea Faculty of Military Medicine, Universitas Pertahanan Republik Indonesia, Bogor, Indonesia
Taureni Hayati Faculty of Military Medicine, Universitas Pertahanan Republik Indonesia, Bogor, Indonesia
Ardhestiro Harnindyo Putro Faculty of Military Medicine, Universitas Pertahanan Republik Indonesia, Bogor, Indonesia

DOI: https://doi.org/10.30701/ijc.1939

Keywords: Diabetes Mellitus, Coronary Artery Disease, In-Stent Restenosis, Percutaneous Coronary Intervention

Abstract

Background: In-Stent Restenosis (ISR) refers to the recurrence of luminal narrowing within the stented segment after Percutaneous Coronary Intervention (PCI) and continues to pose a clinical challenge, especially in individuals with Diabetes Mellitus (DM). Elevated blood glucose levels lead to endothelial injury, persistent inflammation, and excessive neointimal tissue growth, all of which increase the likelihood of ISR.

Methods: This research employed an analytical observational approach with a cross-sectional design and was conducted at a military hospital in Jakarta. Data were collected from the medical records of patients diagnosed with Coronary Artery Disease (CAD) who underwent PCI between January 2021 and December 2023. A total sampling method was applied to all patients who underwent PCI and had a clinically indicated follow-up coronary angiography during the study period, yielding 66 eligible patients. Bivariate analysis was performed using the Chi-square test, followed by multivariable logistic regression to adjust for relevant clinical covariates.

Results: Of the 66 patients included in this study, 44 (66.7%) were diagnosed with DM, and 44 (66.7%) had ISR. Bivariate analysis showed that DM was significantly associated with ISR (OR 4.08; 95% CI: 1.36–12.21; p = 0.0097). Multivariate analysis showed that poor glycemic control remained independently associated with ISR (OR 5.39; 95% CI: 1.04–27.84; p = 0.044), while diabetes status alone was no longer independently associated.

Conclusion: DM is associated with higher ISR after PCI, with poor glycemic control independently associated, underscoring the importance of optimized glycemic management.

Downloads

Download data is not yet available.

References

1. Dadkhah S, Sharain K. Epidemiology and demographics of coronary artery disease. In: Pena M, Osborne A, Peacock WF, editors. Short Stay Management of Chest Pain. Cham: Springer International Publishing; 2022. p. 1–13.
2. Shahjehan RD, Sharma S, Bhutta BS. Coronary artery disease [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564304/
3. Pahwa R, Jialal I. Atherosclerosis [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507799/
4. Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous coronary intervention [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556123/
5. Patel DB, Shah R, Jovin IS. Improving outcomes of percutaneous coronary interventions in patients with stable ischemic heart disease. J Thorac Dis. 2020;12(4):1740–9.
6. Alexandrescu DM, Mitu O, Costache II, Macovei L, Mitu I. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention. Exp Ther Med. 2021;22(4):1141.
7. Giacoppo D, Mazzone PM, Capodanno D. Current management of in-stent restenosis. J Clin Med. 2024;13(8):2377.
8. Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(4):348–72.
9. Cheng G, Chang FJ, Wang Y, You PH, Chen HC. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. Med Sci Monit. 2019; 25:240–7.
10. Wang P, Qiao H, Wang R, Hou R, Guo J. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do. BMC Cardiovasc Disord. 2020;20(1):510.
11. Tanner R, Farhan S, Giustino G, Sartori S, Feng Y. Impact of diabetes mellitus on clinical outcomes after first episode in-stent restenosis PCI: results from a large registry. Int J Cardiol. 2024; 401:131856.
12. Klein LW, Nathan S, Maehara A, Messenger J, Mintz GS. SCAI expert consensus statement on management of in-stent restenosis and stent thrombosis. J Soc Cardiovasc Angiogr Interv. 2023;2(4):100971.
13. Wissing TB, van der Heiden K, Serra SM, Smits AIPM, Bouten CVC. Tissue-engineered collagenous fibrous cap models to systematically elucidate atherosclerotic plaque rupture. Sci Rep. 2022;12(1):5434.
14. Jakubiak GK, Pawlas N, Cieślar G, Stanek A. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Public Health. 2021;18(22):11970.
15. Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1):23.
16. Perkumpulan Endokrinologi Indonesia (PERKENI). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021. Jakarta: PB PERKENI; 2021.
17. Marfella R, Sardu C, D’Onofrio N, Fumagalli C, Scisciola L. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71.
18. American Diabetes Association Professional Practice Committee for Diabetes* . 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S27-S49.
19. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378.
20. Surendran A, Atefi N, Zhang H, Aliani M, Ravandi A. Defining Acute Coronary Syndrome through Metabolomics. Metabolites. 2021;11(10):685.
21. Kementerian Kesehatan Republik Indonesia. Hasil Riset Kesehatan Dasar Tahun 2023. Jakarta: Kemenkes RI; 2023.
22. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.